EUCTR2006-005575-17-IT进行中（未招募）不适用
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety, and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - ND
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 72 人开始时间: 2009年7月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Males < 6 years of age with moderately severe to severe hemophilia A (FVIII activity >= 2%), with previous FVIII replacement therapy experience ( 50 exposure days).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Current or history of FVIII inhibitor.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety and Pharmacokinetics of B-Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - N/AYounger Male Haemophilia A patients < 6 years of age with moderately severe to severe hemophilia A (FVIII:C = 2%), with previous FVIII replacement therapy experience (= 50 exposure days to any FVIII replacement product).EUCTR2006-005575-17-DEWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
进行中（未招募）
1 期
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children With Hemophilia A Estudio abierto para evaluar el tratamiento profiláctico y para caracterizar la eficacia, la seguridad y la farmacocinética del factor VIII recombinante con delección del dominio B sin albúmina (ReFacto® AF) en niños con hemofilia A - N/AEUCTR2006-005575-17-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.65
进行中（未招募）
1 期
A study to compare the difference in effect between treating bleeds after they occur or giving preventative treatment on an ongoing basis, also to determine levels of Factor VIII in the blood following treatment in children with Hemophilia AEUCTR2006-005575-17-ATWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
已完成
不适用
XinthaPER-058-14Pfizer Inc.,
已完成
不适用
An open-label, non-controlled trial of prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation.Invasive fungal infectionJPRN-UMIN000027218ational Hospital Organization Nagoya Medical Center30